During that time, Frank raised more than $1.8 billion in new capital to support AMAG’s growth strategy. Before joining AMAG, he served as chief operating officer and chief financial officer for Molecular Biometrics, Inc. Earlier in his career, Frank also served as chief executive officer for Critical Therapeutics and chief financial officer for Esperion Therapeutics. The first clinical trial of an ex vivo autologous gene therapy begins at the National Institutes of Health. In his current role, Chris is responsible for overseeing corporate strategy, program leadership and management, business development, and communications.
Give your business an edge with our leading industry insights.
Researchers in France report successful results of a clinical trial of an ex vivo autologous gene therapy. He has experience across different modalities and multiple therapeutic areas, including rare, cardiovascular and metabolic diseases having led large global development programs from research through to late phase development. Fulvio earned a Ph.D. in medical genetics at the University of Rome School of Medicine and has published more than 200 articles in major international journals. I changed the setting to allow for remote login as well as to allow for ctrl alt del.
- {
- Before joining AMAG, he served as chief operating officer and chief financial officer for Molecular Biometrics, Inc.
- Results from the first clinical trial of an ex vivo autologous gene therapy are published.
- I changed the setting to allow for remote login as well as to allow for ctrl alt del.
- Prior to joining Audentes, Fulvio was chief scientific officer of Genethon in Évry, France from 2012 to 2017 where he led the development of a robust pipeline of gene therapy programs for blood, liver, and neuromuscular diseases.
- The first clinical trial of an ex vivo autologous gene therapy begins at the National Institutes of Health.
- He has experience across different modalities and multiple therapeutic areas, including rare, cardiovascular and metabolic diseases having led large global development programs from research through to late phase development.
|}
{
|}{
|}
We’re part of gene therapy history – and its future
- Frank joined Orchard in 2018 as chief financial officer and chief business officer.
- He currently oversees key functional areas for the business, including but not limited to, finance, business development, commercial operations, corporate affairs and quality.
- Earlier in his career, he held various positions at the Center for Regenerative Medicine of the University of Modena, Molmed SpA, Genera SpA, and the San Raffaele-Telethon Institute of Gene Therapy in Milan, Italy.
- He is one of the principal scientific founders and current chief executive officer of Orchard Therapeutics, a global gene therapy leader recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe.
- Researchers in France report successful results of a clinical trial of an ex vivo autologous gene therapy.
- Fulvio earned a Ph.D. in medical genetics at the University of Rome School of Medicine and has published more than 200 articles in major international journals.
{
|}
{
|}{
|}
Prior to joining Audentes, Fulvio was chief scientific officer of Genethon in Évry, France from 2012 to 2017 where he led the development of a robust pipeline of gene therapy programs for blood, liver, and neuromuscular diseases. Earlier in his career, he held various positions at the Center for Regenerative Medicine of the University of Modena, Molmed SpA, Genera SpA, and the San Raffaele-Telethon Institute of Gene Therapy in Milan, Italy. He is one of the principal scientific founders and current chief executive officer of Orchard Therapeutics, a global gene therapy leader recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe. In her role as chief medical officer at Orchard Therapeutics, Laura leads a skilled team of professionals in clinical development, medical affairs, diagnostics, newborn screening, and patient advocacy.
{
- In her role as chief medical officer at Orchard Therapeutics, Laura leads a skilled team of professionals in clinical development, medical affairs, diagnostics, newborn screening, and patient advocacy.
- Earlier in his career, Frank also served as chief executive officer for Critical Therapeutics and chief financial officer for Esperion Therapeutics.
- During that time, Frank raised more than $1.8 billion in new capital to support AMAG’s growth strategy.
- His ability to balance scientific rigor with business acumen has been instrumental in optimizing portfolio value and performance while ensuring alignment with corporate strategy.
- In his current role, Chris is responsible for overseeing corporate strategy, program leadership and management, business development, and communications.
- Since that time, his role has expanded to president and chief operating officer of Orchard.
{
|}{
|}
{
|}
|}
NPVM: Alaunos Therapeutics Inc’s Gene Therapy 2 for Oncology
His ability to balance scientific rigor with business acumen has been instrumental in optimizing portfolio value and performance while ensuring alignment with corporate strategy. Frank joined Orchard in 2018 as chief financial officer and chief business officer. Since that time, his role has expanded to president and chief operating officer of Orchard. In his capacities, Frank creates and drives strategies for overall value-creation and long-term Six6s growth of the company. He currently oversees key functional areas for the business, including but not limited to, finance, business development, commercial operations, corporate affairs and quality. Results from the first clinical trial of an ex vivo autologous gene therapy are published.